Switch theme
Sign up to access all valuation multiples
Zhejiang Jiuzhou Pharmaceutical Co Ltd is a China-based pharmaceutical manufacturer. The company is primarily engaged in the manufacturing, research, development, and sale of active pharmaceutical ingredients, intermediates, asymmetric catalyst, and lithium battery materials. Its active pharmaceutical ingredient offerings include Carbamazepine, Duloxetine, Bezafibrate, Meropenem, Sulphadimethoxine Sodium, Oxcarbazepine, and Amprolium, among others. The firm also provides services of new drug contract development and manufacturing organization to the international pharmaceutical giant.
1973
4.9K+
LTM Revenue $743M
LTM EBITDA $178M
$1.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Jiuzhou Pharmaceutical has a last 12-month revenue (LTM) of $743M and a last 12-month EBITDA of $178M.
In the most recent fiscal year, Jiuzhou Pharmaceutical achieved revenue of $716M and an EBITDA of $161M.
Jiuzhou Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Jiuzhou Pharmaceutical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $743M | XXX | $716M | XXX | XXX | XXX |
| Gross Profit | $252M | XXX | $242M | XXX | XXX | XXX |
| Gross Margin | 34% | XXX | 34% | XXX | XXX | XXX |
| EBITDA | $178M | XXX | $161M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 22% | XXX | XXX | XXX |
| EBIT | $119M | XXX | $125M | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $99.9M | XXX | $84.1M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Jiuzhou Pharmaceutical's stock price is CNY 15 (or $2).
Jiuzhou Pharmaceutical has current market cap of CNY 13.5B (or $1.9B), and EV of CNY 11.2B (or $1.6B).
See Jiuzhou Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.6B | $1.9B | XXX | XXX | XXX | XXX | $0.11 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Jiuzhou Pharmaceutical has market cap of $1.9B and EV of $1.6B.
Jiuzhou Pharmaceutical's trades at 2.2x EV/Revenue multiple, and 9.6x EV/EBITDA.
Equity research analysts estimate Jiuzhou Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jiuzhou Pharmaceutical has a P/E ratio of 18.8x.
See valuation multiples for Jiuzhou Pharmaceutical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.9B | XXX | $1.9B | XXX | XXX | XXX |
| EV (current) | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | 8.7x | XXX | 9.6x | XXX | XXX | XXX |
| EV/EBIT | 13.1x | XXX | 12.4x | XXX | XXX | XXX |
| EV/Gross Profit | 6.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 18.8x | XXX | 22.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 109.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialJiuzhou Pharmaceutical's last 12 month revenue growth is 8%
Jiuzhou Pharmaceutical's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $24K for the same period.
Jiuzhou Pharmaceutical's rule of 40 is 37% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Jiuzhou Pharmaceutical's rule of X is 45% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Jiuzhou Pharmaceutical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | -4% | XXX | XXX | XXX |
| Rule of 40 | 37% | XXX | 31% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 45% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $24K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jiuzhou Pharmaceutical acquired XXX companies to date.
Last acquisition by Jiuzhou Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Jiuzhou Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Jiuzhou Pharmaceutical founded? | Jiuzhou Pharmaceutical was founded in 1973. |
| Where is Jiuzhou Pharmaceutical headquartered? | Jiuzhou Pharmaceutical is headquartered in China. |
| How many employees does Jiuzhou Pharmaceutical have? | As of today, Jiuzhou Pharmaceutical has 4.9K+ employees. |
| Is Jiuzhou Pharmaceutical publicy listed? | Yes, Jiuzhou Pharmaceutical is a public company listed on SHG. |
| What is the stock symbol of Jiuzhou Pharmaceutical? | Jiuzhou Pharmaceutical trades under 603456 ticker. |
| When did Jiuzhou Pharmaceutical go public? | Jiuzhou Pharmaceutical went public in 2014. |
| Who are competitors of Jiuzhou Pharmaceutical? | Similar companies to Jiuzhou Pharmaceutical include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Jiuzhou Pharmaceutical? | Jiuzhou Pharmaceutical's current market cap is $1.9B |
| What is the current revenue of Jiuzhou Pharmaceutical? | Jiuzhou Pharmaceutical's last 12 months revenue is $743M. |
| What is the current revenue growth of Jiuzhou Pharmaceutical? | Jiuzhou Pharmaceutical revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Jiuzhou Pharmaceutical? | Current revenue multiple of Jiuzhou Pharmaceutical is 2.1x. |
| Is Jiuzhou Pharmaceutical profitable? | Yes, Jiuzhou Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Jiuzhou Pharmaceutical? | Jiuzhou Pharmaceutical's last 12 months EBITDA is $178M. |
| What is Jiuzhou Pharmaceutical's EBITDA margin? | Jiuzhou Pharmaceutical's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Jiuzhou Pharmaceutical? | Current EBITDA multiple of Jiuzhou Pharmaceutical is 8.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
